| Strategies for successful clinical management of schizophrenia with ziprasidone. | |
| | |
MedLine Citation:
|
PMID: 20658947 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: This review addresses practical clinical issues related to the use of ziprasidone in the treatment of schizophrenia using information from clinical trials, unpublished data, manufacturer's information, and input from an expert faculty of European psychiatrists with extensive experience of the use of ziprasidone, both in clinical trials and in everyday clinical practice. AREAS COVERED IN THIS REVIEW: A Medline search of published data (1998 - 2010) was carried out, together with a review of unpublished data and manufacturer's information. In addition, expert opinion was sought from psychiatrists with extensive experience of ziprasidone in the treatment of schizophrenia in clinical settings across Europe. WHAT THE READER WILL GAIN: This review has been undertaken to determine how the information from clinical trials can be optimally translated into 'real-life' practice and to establish how a decade of experience with ziprasidone in clinical practice can inform its optimal use to maximize effectiveness and minimize side effects. TAKE HOME MESSAGE: Effective use of ziprasidone in everyday clinical practice usually requires rapid titration to doses in the range of 120 - 160 mg/day and administration with proper meals, thereby achieving the high levels of schizophrenia symptom control reported in clinical trials. Additional guidance is provided about effective management of side effects, and appropriate coadministration of benzodiazepines and other agents, to achieve desired outcomes. |
| | |
Authors:
|
Andrea Fagiolini; Fernando Cañas; Bernd Gallhofer; Ilkka Larmo; Pedro Levy; José Manuel Montes; Georgios Papageorgiou; Mathias Zink; Alessandro Rossi |
Related Documents
:
|
20114067 - Genetically modified cells in regenerative medicine and tissue engineering. 22226737 - Novice to expert: the evolution of an advanced practice evaluation tool. 21917397 - Managing the delivery of bad news: an in-depth analysis of doctors' delivery style. 21848727 - The challenges of managing complex lymphoedema/chronic oedema in the uk and canada. 21441787 - Worldwide experience with biosimilar development. 17491527 - Bilobed zenker's diverticula. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 11 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-16 Completed Date: 2011-01-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 2199-220 Citation Subset: IM |
Affiliation:
|
University of Siena School of Medicine, Department of Neuroscience, Viale Bracci 1, 53100 Siena, Italy. andreafagiolini@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antipsychotic Agents
/
administration & dosage,
adverse effects,
pharmacokinetics,
therapeutic use* Comorbidity Humans Piperazines / administration & dosage, adverse effects, pharmacokinetics, therapeutic use* Randomized Controlled Trials as Topic Risk Factors Schizophrenia / drug therapy* Thiazoles / administration & dosage, adverse effects, pharmacokinetics, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Piperazines; 0/Thiazoles; 146939-27-7/ziprasidone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A high-throughput screen for alpha particle radiation protectants.
Next Document: Development and description of GETT: a genetic testing evidence tracking tool.